According to Novartis, Kesimpta is the first targeted B cell ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy.

Kisqali, Pluvicto Drive Novartis (NVS) Amid Competition Per the Zacks analyst, drugs like Entresto, Kesimpta, Pluvicto ... significant exposure to commercial loans, and deteriorating asset quality ...

Novartis revealed this morning that it has ... as well as multiple sclerosis therapy Kesimpta (ofatumumab), which saw sales double to $384 million. Prostate cancer radioligand therapy Pluvicto ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc)Core operating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

“The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The ...

Each vehicle boasts a 1250 Kg payload capacity and introduces Advanced Driver Assistance System (ADAS) technology to India’s Light Commercial Vehicle (LCV) segment. With ten additional segment ...

The last four years have been very challenging for commercial real estate (CRE) owners, developers and investors. And that's probably understating the matter. The first half of 2020 was defined by ...

Showcase your company news with guaranteed exposure both in print and online Get your event in front of thousands of influential leaders in the Cincinnati community ...